The Q1 beat and maintained guidance provide near-term relief, but the underlying business continues to shrink (revenue -4%, EBITDA -40%). Monitor any updates from the strategic review as the primary catalyst. Q2 guidance implies further deterioration, so expect volatility around guidance execution.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 30 $15.38entry
- T+1 · 7mo ago 0.00%α −0.22% · $15.38
- T+5 · 6mo ago −3.84%α −5.56% · $14.79
- T+20 · 6mo ago −11.77%α −16.74% · $13.57
- T+60 · 4mo ago −27.70%α −30.81% · $11.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FMC reported Q1 2026 adjusted loss per share of -$0.23, beating consensus of -$0.38, on revenue of $762M (ex-India) vs $742.4M estimate. The company reaffirmed its full-year 2026 guidance, which implies continued revenue and EBITDA declines. The strategic review announced in February 2026 remains ongoing.
Key Financial Metrics
Key Facts
- Q1 2026 adjusted loss per share -$0.23 vs consensus -$0.38 (beat by $0.15)
- Q1 2026 revenue ex-India $762M, down 4% YoY, above $742.4M consensus
- Full-year 2026 guidance maintained: revenue $3.6B-$3.8B, adjusted EBITDA $670M-$730M, adjusted EPS $1.63-$1.89
- Q2 2026 outlook: revenue $850M-$900M, adjusted EPS $0.16-$0.26 (down ~70% YoY at midpoint)
- Strategic review including potential sale of the company is progressing
- Adjusted EBITDA of $72M was down 40% YoY and above the high end of guidance range
Financial Impact
Adjusted EPS beat of $0.15 vs consensus (-$0.23 vs -$0.38), revenue beat of ~$20M vs consensus, but both down YoY
Risk Factors
- Continued revenue and EBITDA declines in 2026
- Uncertainty regarding the strategic review outcome (potential sale at unfavorable terms)
- High debt load ($4.5B total debt) and negative free cash flow
- Post-patent erosion of Rynaxypyr franchise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000037785-26-000083 |
| Document: fmc-20260429.htm | 0000037785-26-000083 |
| Document: 0000037785-26-000083-index-headers.html | 0000037785-26-000083 |
| Document: 0000037785-26-000083-index.html | 0000037785-26-000083 |
| Document: 0000037785-26-000083.txt | 0000037785-26-000083 |
| 8-K Data (Synthetic) | 0000037785-26-000083 |
Track record
25 reports on FMC
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.91% at T+60 after the Apr 20, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $5.06 Now $5.23 +3.36% settles Nov 19
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $5.64 Now $5.23 −7.27% settles Nov 17
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $6.42 to $5.65 Now $5.23 −18.54% ▼ −11.99% −11.08% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $6.09 to $5.64 Now $5.23 −14.12% ▼ −7.39% −6.80% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $6.20 to $5.63 Now $5.23 −15.65% ▼ −9.19% −6.49% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $6.20 to $5.63 Now $5.23 −15.65% ▼ −9.19% −6.49% vs SPY
- Oct 29, 202618d ago 8-K Bearish 7/10 Entry $6.20 to $5.63 Now $5.23 +15.65% ▲ +9.19% +6.49% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 4/10 Entry $4.47 to $6.42 Now $5.23 +17.00% ▲ +43.62% +44.34% vs SPY
- Oct 21, 202626d ago 8-K Neutral 2/10 Entry $5.02 to $4.75 Now $5.23 +4.18% ▼ −5.38% −6.09% vs SPY
- Oct 21, 202626d ago 8-K Neutral 3/10 Entry $5.02 to $4.75 Now $5.23 +4.18% ▼ −5.38% −6.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers